NanoViricides Reports That It Has Begun Drug Development to Combat Monkeypox Virus

 NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, reports that it has begun drug development to combat the monkeypox virus.